Drug
Albumin-Bound Paclitaxel clinical trials
Also written Abraxane and ABI-007.
A product of Paclitaxel; its studies count on that page too.
- studies test it
- 674
- open now
- 177
- in phase 3
- 51
- first study started
- 1999
Keep track of what changes. Save the Albumin-Bound Paclitaxel studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
673 studies that test it; most in 2019 (48); 1 more planned to start later
| Year | Studies |
|---|---|
| 1999 | 1 |
| 2000 | 1 |
| 2001 | 2 |
| 2003 | 3 |
| 2004 | 3 |
| 2005 | 10 |
| 2006 | 19 |
| 2007 | 17 |
| 2008 | 27 |
| 2009 | 10 |
| 2010 | 13 |
| 2011 | 13 |
| 2012 | 21 |
| 2013 | 30 |
| 2014 | 41 |
| 2015 | 35 |
| 2016 | 31 |
| 2017 | 33 |
| 2018 | 31 |
| 2019 | 48 |
| 2020 | 48 |
| 2021 | 41 |
| 2022 | 47 |
| 2023 | 39 |
| 2024 | 36 |
| 2025 | 38 |
| 2026 | 35 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 7
- Phase 1
- 202
- Phase 2
- 499
- Phase 3
- 51
- Phase 4
- 9
- No phase
- 16
What it is tested for
Each study’s main condition, where its own words name it.
- Melanoma
- 18
Who runs them
Industry 134 · Other 540
Fudan University (27) · Celgene (26) · ImmunityBio, Inc. (21) · M.D. Anderson Cancer Center (17) · Sun Yat-sen University (12) · Tianjin Medical University Cancer Institute and Hospital (11) · Chinese PLA General Hospital (11) · City of Hope Medical Center (9)
Often tested with
Tested in the same studies.
Gemcitabine (197) · Carboplatin (94) · Cisplatin (78) · Bevacizumab (50) · Cyclophosphamide (37) · Capecitabine (35) · Fluorouracil (33) · Leucovorin (27)
Studies
Open first, then newest update. How each study uses Albumin-Bound Paclitaxel is read from its arms, and is right about nine times in ten.
Testing it · 674
- Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE TrialRecruitingPhase 3National Cancer Institute (NCI)NCT06096844Written as Nab-paclitaxel
- A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic CancerRecruitingPhase 1/2Theriva Biologics SLNCT07701486Written as Nab-paclitaxel + Gemcitabine
- MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLCNot yet recruitingPhase 2Peking University People's HospitalNCT07885709Written as Nab-paclitaxel
- PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50%Not yet recruitingPhase 3German Cancer Research CenterNCT07877584Written as nab-Paclitaxel (100 mg/m² )
- Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic AdenocarcinomaRecruitingPhase 3Revolution Medicines, Inc.NCT07805954Written as nab-paclitaxel
- Iparomlimab/Tuvonralimab Combined With Nab-paclitaxel and Cisplatin as Neoadjuvant Therapy for Locally Advanced Cervical CancerRecruitingPhase 2Xijing HospitalNCT07876154Written as nab-paclitaxel
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT03424005Written as Nab-Paclitaxel
- DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic CancerRecruitingPhase 1/2Ohio State University Comprehensive Cancer CenterNCT07705919Written as Nab-paclitaxel
- BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic AdenocarcinomaRecruitingPhase 2Mayo ClinicNCT07226856Written as Nab-paclitaxel
- Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaRecruitingPhase 3Revolution Medicines, Inc.NCT07491445Written as nab-paclitaxel
- A Platform Study in Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 1/2AstraZenecaNCT06996782Written as Nab-paclitaxel
- Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic CancerRecruitingPhase 2Georgetown UniversityNCT06423326Written as Nab-paclitaxel
- Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic AdenocarcinomaRecruitingPhase 2Wake Forest University Health SciencesNCT05825066Written as Nab paclitaxel
- Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/ImmunotherapyRecruitingPhase 2Wake Forest University Health SciencesNCT04253964Written as Nab paclitaxel
- Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal AdenocarcinomaRecruitingPhase 2Northwell HealthNCT07163273Written as Gemcitabine plus nab-Paclitaxel (GnP)
- A Prospective, Multicenter, Randomized Controlled Study on the Efficacy and Safety of Low-dose Carboplatin Combined With Nab-Paclitaxel and Delayed Administration of Serplulimab as First-line Treatment for Advanced Squamous Non-small Cell Lung CancerRecruitingPhase 2People's Hospital of QuzhouNCT07647094Written as Serplulimab, Nab-Paclitaxel, Carboplatin
- Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic AdenocarcinomaRecruitingPhase 2Corcept TherapeuticsNCT07259317Written as Nab-paclitaxel
- Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid TumorsRecruitingPhase 1/2Revolution Medicines, Inc.NCT06445062Written as nab-paclitaxel
- Albumin-bound Paclitaxel (II) in Combination With Gemcitabine as First Line Therapy for Metastatic Pancreatic CancerNot yet recruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07831330Written as Albumin-bound Paclitaxel (Ⅱ) + Gemcitabine
- Utility of ctDNA in Early Switch of First-line Chemotherapy in Metastatic Pancreatic Ductal AdenocarcinomaRecruitingPhase 2University of MiamiNCT07096362Written as Nab Paclitaxel
See all 674 studies that test Albumin-Bound Paclitaxel →
Given in every arm · 412 — Albumin-Bound Paclitaxel is usual care beside what is tested
- A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsRecruitingPhase 1/2Verastem, Inc.NCT07020221Written as Gemcitabine + Nab-paclitaxel
- A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP DeletionRecruitingPhase 2/3Bristol-Myers SquibbNCT07063745Written as Nab-paclitaxel
- Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast CancerRecruitingPhase 2Henan Cancer HospitalNCT06860529Written as Albumin Paclitaxel
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ TrialRecruitingPhase 2National Cancer Institute (NCI)NCT03907475Written as Nab-paclitaxel
- A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.RecruitingPhase 2/3Eikon TherapeuticsNCT07365319Written as Nab-paclitaxel + Carboplatin
- ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast CancerRecruitingPhase 3BioNTech SENCT07173751Written as Nab-paclitaxel/Paclitaxel
- Repurposing Mefloquine for Pancreatic Cancer TreatmentNot yet recruitingPhase 1University of FloridaNCT07875907Written as gemcitabine and nab paclitaxel
- Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]RecruitingPhase 3Merck Sharp & Dohme LLCNCT06422143Written as Nab-paclitaxel
- Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic AdenocarcinomaRecruitingPhase 1Oncomatryx Biopharma S.L.NCT07377045Written as Nab-paclitaxel + Gemcitabine
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast CancerRecruitingPhase 2National Cancer Institute (NCI)NCT03606967Written as Nab-paclitaxel
- Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive MalignanciesRecruitingPhase 1/2Institut de Recherches Internationales ServierNCT05786924Written as Nab-paclitaxel
- Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )RecruitingPhase 3Revolution Medicines, Inc.NCT07621718Written as Nab-paclitaxel
- A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)Not yet recruitingPhase 2Merck Sharp & Dohme LLCNCT07793942Written as Nab-paclitaxel
- Trial of First-line Gemcitabine and Nab-paclitaxel With or Without L-glutamine in Advanced Pancreatic CancerNot yet recruitingPhase 2Jun Gong, MDNCT07864571Written as Nab-paclitaxel
- Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Combined With Monoclonal Antibody in Locally Advanced NSCLCRecruitingPhase 3Shanghai Pulmonary Hospital, Shanghai, ChinaNCT07863999Written as Nab-paclitaxel
- A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)RecruitingPhase 2Bristol-Myers SquibbNCT07492680Written as Nab-paclitaxel
- A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic CancerRecruitingPhase 2M.D. Anderson Cancer CenterNCT07283705Written as Nab-paclitaxel
- A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS MutationRecruitingPhase 1/2Genfleet Therapeutics (Shanghai) Inc.NCT07678593Written as Nab paclitaxel
- A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)RecruitingPhase 2Merck Sharp & Dohme LLCNCT07221474Written as Nab-paclitaxel
- Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast CancerRecruitingPhase 1National Cancer Institute (NCI)NCT05422794Written as Nab-paclitaxel
Showing 20 of 412.
As the comparator · 52 — what is tested is compared with Albumin-Bound Paclitaxel
- Antibody-Drug Conjugate Plus Immunotherapy Versus Immunotherapy Plus Chemotherapy for Extensive Transurethrally Unresectable Very-High-Risk Non-Muscle-Invasive Bladder CancerNot yet recruitingPhase 2Tianjin Medical University Second HospitalNCT07879469Written as Toripalimab and Nab-Paclitaxel
- Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaRecruitingPhase 3Immuneering CorporationNCT07562152Written as GnP
- A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07060807Written as Nab-paclitaxel
- A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)RecruitingPhase 2Merck Sharp & Dohme LLCNCT06731907Written as Nab-paclitaxel
- A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06312176Written as Nab-paclitaxel
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06841354Written as Nab-paclitaxel
- A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary CancersRecruitingPhase 2AbbVieNCT07769502Written as Nab-Paclitaxel
- A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04)RecruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT07729956Written as Nab-paclitaxel
- A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)RecruitingPhase 3AstraZenecaNCT06103864Written as Nab-paclitaxel
- A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic CancerRecruitingPhase 2/3HutchmedNCT06361888Written as Nab-paclitaxel Plus Gemcitabine
- Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic CancerRecruitingPhase 3NRG OncologyNCT06958328Written as Nab-paclitaxel
- SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous MelanomaRecruitingPhase 3Immatics US, Inc.NCT06743126Written as Albumin-Bound Paclitaxel
- A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)RecruitingPhase 2/3Bristol-Myers SquibbNCT06926868Written as Nab-paclitaxel
- A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03)RecruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT07648914Written as Albumin-Bound Paclitaxel
- SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung CancerNot yet recruitingPhase 2/3Shanghai Chest HospitalNCT07662811Written as Nab-Paclitaxel
- A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine TherapyRecruitingPhase 3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.NCT07071337Written as Nab-paclitaxel
- Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic CancerRecruitingPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT07238283Written as nab-paclitaxel; gemcitabine
- A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBCNot yet recruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07040644Written as Nab-paclitaxel
- Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast CancerRecruitingPhase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06255392Written as Paclitaxel-albumin
- Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic CancerRecruitingPhase 3Fudan UniversityNCT06250972Written as Gemcitabine, Nab-paclitaxel, Irinotecan
Showing 20 of 52.